NeoStem Announces CEO Dr. Robin L. Smith Selected as Finalist for EY Entrepreneur of the Year 2014 Award

New York, May 21, 2014 — NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Dr. Robin L. Smith, Chairman and CEO, has been a selected as a finalist for 2014 in the New York region for the EY Entrepreneur of the Year Award.   The EY Entrepreneur Of The Year award recognizes entrepreneurs who demonstrate excellence and success in the areas of innovation, financial performance and personal commitment to their businesses and communities. The finalists were selected by a panel of independent judges. Award winners will be announced at a special gala event on Tuesday, June 17, 2014 at the Marriott Marquis in New York City.    "I am honored to be considered as a finalist in this prestigious competition along with such an exciting group of innovative business leaders in market leading companies," said Dr. Robin Smith. "NeoStem is committed to developing cell therapy products with the potential to revolutionize health care around the globe, and becoming a finalist for this award recognizes all of the progress we have made to date."   Regional award winners are eligible for consideration for the EY Entrepreneur Of The Year 2014 National program.  Award winners in several national categories, as well as the EY Entrepreneur Of The Year National Overall Award winner, will be announced at the annual awards gala in Palm Springs, California, on November 15, 2014. The awards are the culminating event of the EY Strategic Growth Forum®.     About NeoStem, Inc.   NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.www.neostem.com      About EY Entrepreneur Of The Year   According to EY, the EY Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.   EY refers to the global organization and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity.     Forward-Looking Statements   This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, CD34 Cell Program, T Regulatory Cell Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.